Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + sitagliptin (Alkem Laboratories)
- Development stage
- Phase 4
- Lead developer
- Alkem Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alsita-M is a fixed-dose combination of the biguanide metformin and the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin. It is developed and marketed by Alkem Laboratories and Indus Life Sciences for the management of type 2 diabetes mellitus. Metformin works by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Sitagliptin works by inhibiting the DPP-4 enzyme, which slows the inactivation of incretin hormones (such as GLP-1 and GIP), thereby increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. Together, these complementary mechanisms provide glycemic control in patients with type 2 diabetes.
- Brand names
- Alsita MAlsita M IRAlsita-MAlsita-M ERAlsita-M Forte
- Other names
- metformin + sitagliptinsitagliptin + metforminsitagliptin phosphate + metformin hydrochloride
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)V-ATPase (Vacuolar-type H+-ATPase)DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)GSEC (Gamma-Secretase Complex)
Beyond the preview
Go deeper on metformin + sitagliptin (Alkem Laboratories).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + sitagliptin (Alkem Laboratories).